$TRVI
Trevi Therapeutics, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019031528 Filed on August 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q4 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.890M $1.410M $940.0K
YoY Change 101.06% 127.42%
% of Gross Profit
Research & Development $5.528M $4.520M $3.439M
YoY Change 60.74% 182.5%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $10.00K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $7.417M $5.930M $4.380M
YoY Change 69.34% 167.12%
Operating Profit -$7.417M -$4.380M
YoY Change 69.34%
Interest Expense $229.0K $40.00K $51.00K
YoY Change 349.02% -125.0%
% of Operating Profit
Other Income/Expense, Net $66.00K -$140.0K -$503.0K
YoY Change -113.12%
Pretax Income -$7.351M -$6.030M -$4.883M
YoY Change 50.54% 152.3%
Income Tax -$5.000K -$50.00K -$25.00K
% Of Pretax Income
Net Earnings -$7.346M -$5.980M -$4.858M
YoY Change 51.21% 151.26%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$412.2K -$387.3K -$315.8K
COMMON SHARES
Basic Shares Outstanding 17.83M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2018 Q4 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $71.39M $7.200M
YoY Change
Cash & Equivalents $71.39M $7.202M $7.058M
Short-Term Investments
Other Short-Term Assets $2.970M $1.440M
YoY Change
Inventory
Prepaid Expenses $2.970M $1.438M
Receivables
Other Receivables
Total Short-Term Assets $74.61M $8.824M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $139.0K $149.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $1.550M
YoY Change
Total Long-Term Assets $508.0K $1.702M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $74.61M $8.824M
Total Long-Term Assets $508.0K $1.702M
Total Assets $75.12M $10.53M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.663M $603.0K
YoY Change
Accrued Expenses $4.351M $2.073M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $7.105M $2.676M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.100M
YoY Change
Other Long-Term Liabilities $310.0K $510.0K
YoY Change
Total Long-Term Liabilities $310.0K $1.610M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.105M $2.676M
Total Long-Term Liabilities $310.0K $1.610M
Total Liabilities $7.410M $4.280M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$100.3M -$109.5M
YoY Change
Common Stock $18.00K $4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $67.70M -$109.5M -$95.34M
YoY Change
Total Liabilities & Shareholders Equity $75.12M $10.53M
YoY Change

Cashflow Statement

Concept 2019 Q2 2018 Q4 2018 Q2
OPERATING ACTIVITIES
Net Income -$7.346M -$5.980M -$4.858M
YoY Change 51.21% 151.26%
Depreciation, Depletion And Amortization $10.00K $10.00K $10.00K
YoY Change 0.0%
Cash From Operating Activities -$5.060M -$4.730M -$5.610M
YoY Change -9.8% 66.55%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$90.00K -$10.00K
YoY Change -100.0% 800.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$90.00K -$10.00K
YoY Change -100.0% 800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 63.50M -1.510M -3.280M
YoY Change -2035.98% -18.38%
NET CHANGE
Cash From Operating Activities -5.060M -4.730M -5.610M
Cash From Investing Activities 0.000 -90.00K -10.00K
Cash From Financing Activities 63.50M -1.510M -3.280M
Net Change In Cash 58.44M -6.330M -8.900M
YoY Change -756.63% 34.68%
FREE CASH FLOW
Cash From Operating Activities -$5.060M -$4.730M -$5.610M
Capital Expenditures $0.00 -$90.00K -$10.00K
Free Cash Flow -$5.060M -$4.640M -$5.600M
YoY Change -9.64% 63.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
101929904
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
438600
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
438600
us-gaap Operating Income Loss
OperatingIncomeLoss
-7522000
trvi Change In Fair Value Of Redeemable Convertible Preferred Stock Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockLiability
1266000
CY2019Q2 trvi Change In Fair Value Of Obligation For Loan Success Fee
ChangeInFairValueOfObligationForLoanSuccessFee
-163000
CY2018Q2 trvi Change In Fair Value Of Obligation For Loan Success Fee
ChangeInFairValueOfObligationForLoanSuccessFee
-68000
us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
2573000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12852000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11112000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.32
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-25.45
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5535907
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
436598
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
7417000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
8824000
CY2018Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1534000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
350000
CY2019Q2 us-gaap Security Deposit
SecurityDeposit
19000
CY2018Q4 us-gaap Security Deposit
SecurityDeposit
19000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
139000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
4380000
us-gaap Operating Expenses
OperatingExpenses
12229000
us-gaap Operating Expenses
OperatingExpenses
7522000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
149000
CY2019Q2 us-gaap Assets
Assets
75116000
CY2018Q4 us-gaap Assets
Assets
10526000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2663000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
603000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4351000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2073000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
91000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7105000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2676000
CY2018Q4 trvi Loan Success Fee
LoanSuccessFee
460000
CY2018Q4 trvi Series C Redeemable Convertible Preferred Stock Liability
SeriesCRedeemableConvertiblePreferredStockLiability
1096000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8866000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5802000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1889000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
941000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3363000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1720000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71387000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7202000
CY2019Q2 trvi Tax Credit And Other Receivables
TaxCreditAndOtherReceivables
251000
CY2018Q4 trvi Tax Credit And Other Receivables
TaxCreditAndOtherReceivables
184000
CY2019Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2970000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1438000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
74608000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
308000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
18000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
168002000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100317000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109498000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
67703000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-109494000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75116000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10526000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17834570
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17834570
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5528000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3439000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7417000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4380000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12229000
CY2018Q2 trvi Change In Fair Value Of Redeemable Convertible Preferred Stock Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockLiability
422000
trvi Change In Fair Value Of Obligation For Loan Success Fee
ChangeInFairValueOfObligationForLoanSuccessFee
-215000
trvi Change In Fair Value Of Obligation For Loan Success Fee
ChangeInFairValueOfObligationForLoanSuccessFee
-80000
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
229000
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
38000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
287000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
83000
CY2018Q2 us-gaap Interest Expense
InterestExpense
51000
us-gaap Interest Expense
InterestExpense
174000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
66000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-503000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
72000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1437000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7351000
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4883000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12157000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8959000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5000
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-25000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-50000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7346000
CY2019Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-1332000
CY2018Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-175000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-1535000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-370000
CY2019Q2 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
686000
CY2018Q2 us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
1293000
us-gaap Redeemable Preferred Stock Dividends
RedeemablePreferredStockDividends
2239000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6700000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5976000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.62
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10571736
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
438606
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-115476000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
237000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-686000
CY2019Q2 trvi Accretion Amortization Of Premium Discount On Issuance Of Redeemable Convertible Preferred Stock
AccretionAmortizationOfPremiumDiscountOnIssuanceOfRedeemableConvertiblePreferredStock
-19000
CY2019Q2 trvi Accretion Of Discount On Investor Rightsobligation
AccretionOfDiscountOnInvestorRightsobligation
-168000
CY2019Q2 trvi Adjustment For Excess Of Fair Value Liquidation Redeemable Convertible Preferred Stock
AdjustmentForExcessOfFairValueLiquidationRedeemableConvertiblePreferredStock
1716000
CY2019Q2 trvi Accretion Of Issuance Costs On Redeemable Convertible Preferred Stock
AccretionOfIssuanceCostsOnRedeemableConvertiblePreferredStock
-197000
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
127504000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
102000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-1293000
CY2018Q2 trvi Accretion Amortization Of Premium Discount On Issuance Of Redeemable Convertible Preferred Stock
AccretionAmortizationOfPremiumDiscountOnIssuanceOfRedeemableConvertiblePreferredStock
-4000
CY2018Q2 trvi Accretion Of Discount On Investor Rightsobligation
AccretionOfDiscountOnInvestorRightsobligation
-32000
CY2018Q2 trvi Adjustment For Excess Of Fair Value Liquidation Redeemable Convertible Preferred Stock
AdjustmentForExcessOfFairValueLiquidationRedeemableConvertiblePreferredStock
239000
CY2018Q2 trvi Accretion Of Issuance Costs On Redeemable Convertible Preferred Stock
AccretionOfIssuanceCostsOnRedeemableConvertiblePreferredStock
-28000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-95337000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
383000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-2239000
trvi Accretion Amortization Of Premium Discount On Issuance Of Redeemable Convertible Preferred Stock
AccretionAmortizationOfPremiumDiscountOnIssuanceOfRedeemableConvertiblePreferredStock
-24000
trvi Accretion Of Discount On Investor Rightsobligation
AccretionOfDiscountOnInvestorRightsobligation
-201000
trvi Adjustment For Excess Of Fair Value Liquidation Redeemable Convertible Preferred Stock
AdjustmentForExcessOfFairValueLiquidationRedeemableConvertiblePreferredStock
1994000
trvi Accretion Of Issuance Costs On Redeemable Convertible Preferred Stock
AccretionOfIssuanceCostsOnRedeemableConvertiblePreferredStock
-234000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
127504000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-84428000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-2573000
trvi Accretion Amortization Of Premium Discount On Issuance Of Redeemable Convertible Preferred Stock
AccretionAmortizationOfPremiumDiscountOnIssuanceOfRedeemableConvertiblePreferredStock
-8000
trvi Accretion Of Discount On Investor Rightsobligation
AccretionOfDiscountOnInvestorRightsobligation
-65000
trvi Adjustment For Excess Of Fair Value Liquidation Redeemable Convertible Preferred Stock
AdjustmentForExcessOfFairValueLiquidationRedeemableConvertiblePreferredStock
498000
trvi Accretion Of Issuance Costs On Redeemable Convertible Preferred Stock
AccretionOfIssuanceCostsOnRedeemableConvertiblePreferredStock
-55000
us-gaap Depreciation
Depreciation
19000
us-gaap Depreciation
Depreciation
6000
trvi Change In Fair Value Loan Success Fee
ChangeInFairValueLoanSuccessFee
215000
trvi Change In Fair Value Loan Success Fee
ChangeInFairValueLoanSuccessFee
80000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
60000
us-gaap Share Based Compensation
ShareBasedCompensation
383000
us-gaap Share Based Compensation
ShareBasedCompensation
190000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
67000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
38000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1532000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1559000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1714000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
180000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2259000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-852000
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
12000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9157000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9564000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4812000
trvi Payments For Final Fees On Term Loan
PaymentsForFinalFeesOnTermLoan
532000
trvi Payments For Loan Success Fee
PaymentsForLoanSuccessFee
675000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
38000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
9963000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
51150000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1075000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
13950000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73351000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5331000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
64185000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14962000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22020000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7058000
us-gaap Interest Paid Net
InterestPaidNet
152000
trvi Income Tax Credits Exchanged For Cash
IncomeTaxCreditsExchangedForCash
8000
trvi Initial Public Offering Costs Included In Accounts Payable And Accrued Expenses
InitialPublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
597000
trvi Dividend Accrued On Redeemable Convertible Preferred Stock
DividendAccruedOnRedeemableConvertiblePreferredStock
2239000
trvi Dividend Accrued On Redeemable Convertible Preferred Stock
DividendAccruedOnRedeemableConvertiblePreferredStock
2573000
trvi Accretion On Redeemable Convertible Preferred Stock
AccretionOnRedeemableConvertiblePreferredStock
-1535000
trvi Accretion On Redeemable Convertible Preferred Stock
AccretionOnRedeemableConvertiblePreferredStock
-370000
us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Nature of the Business </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trevi Therapeutics, Inc. (&#8220;Trevi&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The Company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (&#8220;IPF&#8221;), and levodopa-induced dyskinesia (&#8220;LID&#8221;) in patients with Parkinson&#8217;s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Due to nalbuphine&#8217;s mechanism of action as a modulator of opioid receptors, the Company believes nalbuphine ER has the potential to be effective in treating each of these conditions. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nalbuphine ER is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed &#954;-opioid receptor agonist and &#956;-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in both the United States and Europe. The &#954;- and &#956;-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine&#8217;s mechanism of action also mitigates the risk of abuse associated with &#956;-opioid agonists because it antagonizes, or blocks, the &#956;-opioid receptor. Nalbuphine is currently the only opioid approved for marketing that is not classified as a controlled substance in the United States and most of Europe. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 22, 2019, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a one-for 9.5 reverse stock split of the Company&#8217;s common stock, which resulted in a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s redeemable convertible preferred stock. Accordingly, all share and per share amounts in the condensed consolidated financial statements have been retrospectively adjusted, where applicable, to reflect the effect of the reverse stock split and adjustments of the redeemable convertible preferred stock conversion for all periods presented.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 9, 2019, the Company completed its initial public offering (&#8220;IPO&#8221;) and a concurrent private placement in which it issued and sold an aggregate of 7,000,000 shares of common stock at an offering price of $10.00 per share, for net proceeds of $62.1 million, after deducting aggregate underwriting discounts and commissions and private placement agent fees of $4.9 million and other offering expenses of&nbsp;&nbsp;$3.0 million.&nbsp;&nbsp;The Company&#8217;s common stock began trading on The Nasdaq Global Market on May 7, 2019 under the ticker symbol &#8220;TRVI&#8221;.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO, the Company&#8217;s outstanding redeemable convertible preferred stock, including the accrued dividends theron, automatically converted into shares of the Company&#8217;s common stock.&nbsp;&nbsp;Upon such conversion of the redeemable convertible preferred stock, the Company reclassified the carrying values of the redeemable convertible preferred stock to common stock and additional paid-in capital.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.&nbsp;&nbsp;Since inception, the Company has financed its operations primarily through private placements of its redeemable convertible preferred stock and convertible notes as well as borrowings under a term loan facility, and most recently, with proceeds from the IPO and concurrent private placement completed in May 2019.&nbsp;&nbsp;The Company has incurred recurring losses since inception, including net losses attributable to the Company of $12.1 million for the six months ended June 30, 2019 and $20.5 million for the year ended December 31, 2018.&nbsp;&nbsp;In addition, as of June 30, 2019, the Company had an accumulated deficit of $100.3&#160;million. The Company expects to continue to generate operating losses for the foreseeable future. As of <font style="color:#000000;">August 12, 2019</font>, the issuance date of these Condensed Consolidated Financial Statements, the Company expects that its cash and cash equivalents of $71.4&#160;million as of June 30, 2019, will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the date of issuance of these Condensed Consolidated Financial Statements.</p>
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
59000
CY2019Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
27000
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
42000
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.130
trvi Number Of New Leases
NumberOfNewLeases
0
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
399000
CY2017 trvi Preferred Stock Risk Free Rate
PreferredStockRiskFreeRate
0.0195
us-gaap Convertible Preferred Stock Settlement Terms
ConvertiblePreferredStockSettlementTerms
In addition, TPG had the right to purchase, on the same terms and conditions as the Series B Initial Closing, including the $1.15 per share purchase price, the lesser of 4,347,826 additional shares of Series B Preferred Stock and the number of shares equal to 25% of the total number of shares it previously purchased for cash under the Series B Purchase Agreement (the “Additional Series B Shares”). This additional right was exercisable until the date six months after the completion date of the Company’s Phase 2b/3 clinical trial of nalbuphine ER in patients with uremic pruritus.
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.06
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of the expenses during the reporting periods. Significant estimates and assumptions reflected in these Condensed Consolidated Financial Statements include, but are not limited to the recognition of research and development (&#8220;R&amp;D&#8221;) expenses and the valuation of redeemable convertible preferred stock, common stock and stock-based awards. On an ongoing basis, management evaluates its estimates in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </p>
CY2018Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
16200000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.09
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.67
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.04
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
68000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
138000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
138000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
131000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
24000
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
499000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
100000
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
23000
CY2018Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
30000
us-gaap Operating Lease Payments
OperatingLeasePayments
57000
us-gaap Operating Lease Payments
OperatingLeasePayments
56000
CY2013Q4 us-gaap Share Price
SharePrice
1.00
CY2019Q2 trvi Accrued Research Liabilities
AccruedResearchLiabilities
3044000
CY2018Q4 trvi Accrued Research Liabilities
AccruedResearchLiabilities
942000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.60
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.26
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.69
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
8.19
CY2019Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for 9.5
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-20500000
CY2019Q2 trvi Loan Success Fee Payable
LoanSuccessFeePayable
675000
CY2018 trvi Capitalized Deferred Offering Costs
CapitalizedDeferredOfferingCosts
1534000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
379000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
424000
CY2019Q2 trvi Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1765000
CY2018Q4 trvi Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1337000
CY2019Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1178000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
561000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
477000
CY2019Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
602000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
584000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
144000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
70000
trvi Loan Success Fee Payable Fairvalue
LoanSuccessFeePayableFairvalue
0
CY2018 trvi Loan Success Fee Payable Fairvalue
LoanSuccessFeePayableFairvalue
460000
CY2019Q2 trvi Non Cash Charge
NonCashCharge
163000
CY2018Q2 trvi Non Cash Charge
NonCashCharge
68000
trvi Non Cash Charge
NonCashCharge
215000
trvi Non Cash Charge
NonCashCharge
80000
CY2019Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2778812
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10690261
trvi Effective Date Of Restated Certificate Of Incorporation
EffectiveDateOfRestatedCertificateOfIncorporation
2019-05-09
CY2013Q4 trvi Convertible Preferred Stock Additional Shares Authorized For Issuance
ConvertiblePreferredStockAdditionalSharesAuthorizedForIssuance
2000000
CY2017 trvi Preferred Stock Volatility Rate
PreferredStockVolatilityRate
0.780
CY2017 trvi Preferred Stock Weighted Estimated Maturity Term
PreferredStockWeightedEstimatedMaturityTerm
P2Y8M15D
CY2019Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2018 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
us-gaap Common Stock Voting Rights
CommonStockVotingRights
holders of redeemable convertible preferred stock were entitled to vote as one class with the holders of common stock on any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of a meeting), and each holder of outstanding shares of redeemable convertible preferred stock was entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of redeemable convertible preferred stock held by such holder were convertible as of the record date for determining stockholders entitled to vote on the matter.
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1077148
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
667102
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
35745
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
5592
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
14736
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1688177
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
592456
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1095721
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
trvi Sharebased Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Contractual Term
SharebasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageContractualTerm
P9Y4M24D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5857000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3946000
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2853000
CY2019Q2 trvi Share Based Compensation Arrangement By Share Based Payment Award Options Unvested In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedInPeriodFairValue
1093000
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
237000
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
102000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1688177
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
69866974

Files In Submission

Name View Source Status
0001564590-19-031528-index-headers.html Edgar Link pending
0001564590-19-031528-index.html Edgar Link pending
0001564590-19-031528.txt Edgar Link pending
0001564590-19-031528-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trvi-10q_20190630.htm Edgar Link pending
trvi-20190630.xml Edgar Link completed
trvi-20190630.xsd Edgar Link pending
trvi-20190630_cal.xml Edgar Link unprocessable
trvi-20190630_def.xml Edgar Link unprocessable
trvi-20190630_lab.xml Edgar Link unprocessable
trvi-20190630_pre.xml Edgar Link unprocessable
trvi-ex311_92.htm Edgar Link pending
trvi-ex312_91.htm Edgar Link pending
trvi-ex321_89.htm Edgar Link pending
trvi-ex322_90.htm Edgar Link pending